Life Insurance
Consensus Index

AI Consensus Fit Review

Corebridge Financial Life Insurance Fit Review for People With Heart Disease

Corebridge Financial is a mixed-to-good fit for life insurance with a heart disease history, not a guaranteed one.

Research: 2026-09-227 usable platform responsesRead the methodology ↗

Share

Answer Capsule

Corebridge Financial is a mixed-to-good fit for life insurance with a heart disease history, not a guaranteed one. Four of seven platforms named it during ranking discovery, with an average listed rank of 3.0 and a best rank of 1 (openai, google). Its strongest case is breadth: fully underwritten Select-a-Term, simplified-issue SimpliNow Legacy, and no-health-question Guaranteed Issue Whole Life give applicants multiple paths [1]. The main limitation is that no platform verified heart-disease-specific approval rates, table ratings, or premiums, and one independent reviewer reports the heart-disease underwriting edge has become "hit or miss" since 2024 [3].

Research Snapshot

FieldFinding
Platform mentions in ranking stage4 of 7 platforms (anthropic, google, openai, perplexity)
Share of included platform responses57.1%
Average listed rank3.0
Best listed rank1 (google, openai)
Relevant product/model/planSelect-a-Term term life; SimpliNow Legacy simplified issue; Guaranteed Issue Whole Life
Overall use-case fitMixed; platform fit ratings ranged from "strong" (google) to "uncertain" (kimi)
Research date2026-09-22

Why Corebridge Financial Qualified for This Study

Questions This Section Answers

  • Is Corebridge Financial a good choice for life insurance for people with heart disease?
  • How many AI platforms named Corebridge Financial for heart disease life insurance, and at what rank?

Corebridge qualified because independent reviewers repeatedly name it as a heart-condition carrier, and because it sells products across the underwriting spectrum. Policygenius analysis cited by two platforms found Corebridge offers traditional coverage more often and at lower rates than competitors for people with various heart issues, and that shoppers with heart disease history most frequently find their best rates through Corebridge [5]. Insure.com describes Corebridge as more accessible for shoppers with pre-existing conditions [8].

The ranking evidence is real but not unanimous. Four of seven platforms named Corebridge during ranking discovery; deepseek, grok, and kimi did not name it in the ranking stage, though grok and kimi still produced fit research. Google ranked it first and described its underwriters as comfortable working complex cardiac files rather than auto-declining [10]. Perplexity ranked it seventh and called it a mixed fit, strong mainly for small final-expense coverage [11].

Platform fit ratings diverged: google rated it "strong," anthropic and grok "good," openai, deepseek, and perplexity "mixed," and kimi "uncertain." That spread is itself the finding: Corebridge is a legitimate candidate for this use case, but the evidence does not support calling it the best or most predictable option.

The Product, Model, Plan, or Service Most Relevant to Life Insurance for People With Heart Disease

Questions This Section Answers

  • Which Corebridge Financial product should a buyer with heart disease choose: Select-a-Term, SimpliNow Legacy, or Guaranteed Issue Whole Life?
  • Does Corebridge Financial's Select-a-Term require a medical exam for someone with a cardiac history?

Three Corebridge products matter for this use case, and they serve different cardiac profiles.

Select-a-Term is the primary fully underwritten term product. It offers multiple durations, including 10-year, 35-year, and lengths between 15 and 30 years [13]. One independent review calls it one of the most flexible term policies in the industry [15], and another reports 18 available term lengths [16]. Minimum coverage is $100,000 [17], with issue ages 20–80 and riders including accidental death benefit, child rider, terminal illness rider, and waiver of premium [18]. Select-a-Term is fully underwritten and typically requires a medical exam, with underwriting taking 2–6 weeks [19]. Policies are convertible to permanent coverage without a new medical exam [21].

SimpliNow Legacy is simplified-issue whole life: ages 50–80, coverage from $5,000 to $35,000, short application, no medical exam required [23]. Corebridge's own materials state simplified underwriting may cost more and provide less coverage than fully underwritten policies, and approval is not guaranteed [25].

Guaranteed Issue Whole Life accepts applicants who meet age qualifications with no medical exam and no health questions [26]. Forbes reports guaranteed acceptance for ages 50–80 with coverage from $5,000 to $25,000 [28]. One rate sheet states total GIWL coverage on any person cannot exceed $25,000 in the aggregate [30]. Deepseek's research describes the age range as 50–85 [32], a conflict buyers should verify.

Google's research also names the Quality of Life suite, whose accelerated benefit riders can be triggered by a qualifying critical illness such as a major heart attack [33]. This is platform-reported and should be confirmed against the policy form.

What the AI Platforms Agreed About

Questions This Section Answers

  • What do AI platforms agree on about Corebridge Financial for heart disease life insurance applicants?
  • Is Corebridge Financial's Guaranteed Issue Whole Life a reliable fallback for someone with heart disease?

Three findings drew broad agreement.

First, Corebridge offers a genuine range of underwriting pathways. OpenAI, anthropic, deepseek, perplexity, grok, and kimi all describe term, permanent, simplified-issue, and/or guaranteed-issue options in the same portfolio [35]. That breadth is the core reason the carrier keeps appearing in heart-disease research.

Second, the guaranteed-issue fallback is real but limited. Multiple platforms agree Guaranteed Issue Whole Life requires no medical exam or health questions, and that it pays a limited death benefit during the first two years — generally 110% of premiums paid — with suicide limited to a premium refund [39]. Coverage caps at $25,000 in the aggregate per one rate sheet [43].

Third, financial strength is solid. Corebridge holds an A (Excellent) rating from AM Best, plus A+ from Standard & Poor's and A2 from Moody's, per independent review [45]. Ratings are not a guarantee of claims payment or underwriting acceptance [47].

Where the AI Platforms Disagreed or Were Uncertain

Questions This Section Answers

  • Is Corebridge Financial still competitive for heart disease underwriting in 2026, or has its appetite changed?
  • How does Corebridge Financial's customer satisfaction compare with other carriers for heart disease applicants?

The sharpest conflict is whether Corebridge's heart-disease underwriting edge still exists. Policygenius-derived evidence says Corebridge will offer best rates for pericarditis, aortic stenosis, mitral stenosis, and similar conditions, and that coverage is likely several months after bypass surgery [48]. Against that, RiskQuoter's 2026 review — cited by both anthropic and grok — reports less aggressive offers for impaired risk in 2024–2025 and describes heart disease as now "hit or miss" [50]. Google's research takes the opposite view, describing Corebridge as "highly competitive and medically progressive" with strong table-rated pricing [53]. This conflict is unresolved in the supplied evidence.

Customer satisfaction is a second disagreement point. NerdWallet reports Corebridge ranked No. 19 of 22 companies in J.D. Power's 2025 U.S. Life Insurance Study and drew far more than expected complaints to state regulators over three years [55]. Deepseek's review of Trustpilot describes mixed customer-experience signals [57]. No platform supplied cardiac-specific service data.

Third, product naming is inconsistent. Sources alternate between "SimpliNow Legacy" and "Simplified Issue Whole Life," and it is unclear whether these are distinct products or one product with alternate naming [58]. One reviewer also calls SimpliNow Legacy "unreliable" without detail [51].

Finally, kimi found no independent confirmation of Corebridge's cardiac underwriting guidelines, table ratings, or impaired-risk pricing, and rated the fit "uncertain" [60]. That absence is a gap in public evidence, not proof of weakness.

Use-Case-Specific Features and Capabilities

Questions This Section Answers

  • What cardiac conditions does Corebridge Financial underwrite favorably, and what stability period applies after a stent or bypass?
  • Does Corebridge Financial's Select-a-Term convert to permanent coverage without new underwriting if a heart condition worsens?

Corebridge's relevant capabilities for a heart-disease applicant cluster into four areas.

Underwriting tolerance. Google's research reports Corebridge underwriters manually work complex cardiac files — such as a heart attack combined with diabetes — rather than issuing automatic rejections [63]. Corebridge's own underwriting explainer describes traditional, simplified, accelerated, and guaranteed-issue pathways with different tradeoffs [64].

Stability and documentation requirements. Google's research cites a 6-to-12-month stabilization period after a stent, bypass, or heart attack before traditional policies are considered, plus extensive records including ECG, stress tests, catheterization reports, and ejection fraction history [65]. Kimi's industry-level research cites 12+ months stability and ejection fraction of 45% or above, ideally 50%+ [66]. These are platform-reported industry benchmarks, not confirmed Corebridge rules.

Accelerated underwriting. Corebridge describes Agile Underwriting+ as a streamlined pathway that may avoid an exam, labs, or attending-physician-statement records for eligible applications [68]. One independent review reports over 60% of term applications qualify, without clarifying whether heart-disease applicants are included in that figure [69]. NAIC cautions that accelerated underwriting does not always produce issuance and some applicants still need traditional underwriting [70]. Perplexity's research notes AU+ cases that cannot be decided pivot to full underwriting [71].

Conversion. Select-a-Term policies can convert to permanent coverage without a new medical exam, through the level-premium period or age 70, whichever comes first [72]. This matters if a cardiac condition worsens mid-term.

Pricing, Fees, Contracts, and Ongoing Costs

Questions This Section Answers

  • How much does Corebridge Financial's Guaranteed Issue Whole Life cost per month for a buyer with heart disease?
  • What fees and first-two-year benefit limits apply to Corebridge Financial's simplified and guaranteed-issue policies?

No platform verified a heart-disease-specific premium. Pricing confidence is low across all seven platform responses.

What is documented: Guaranteed Issue Whole Life premiums start at $22 per month for $5,000 of coverage per Corebridge Direct marketing, with one rate sheet stating monthly premiums include a $24 annual policy fee and that rates are guaranteed not to increase [74]. Coverage runs $5,000–$25,000 [76]. SimpliNow Legacy runs $5,000–$35,000 [77].

For term, one independent ranking reports Corebridge's average 20-year, $500,000 term premium at $664 annually [78], and another review calls its term rates competitive but not the cheapest on the market [79]. Google's research cites a low monthly modal factor of 8.45% and competitive Special Class rates on rated cases, with table-rated heart applicants potentially paying 150%–250% of standard premiums [80]. That table-rating range is platform-reported and unverified.

Contract terms to weigh: Select-a-Term lasts for the selected term with conversion and renewal provisions that vary by policy [82]. SimpliNow Legacy and Guaranteed Issue Whole Life limit benefits during the first two years, generally to 110% of premiums paid, with suicide limited to a premium refund [83]. One platform reports late payment beyond 60 days may lapse a policy without notice [87]. No product-specific policy fee, application fee, or rider charge for this buyer was verified from reviewed public sources [82].

Best Suited For

Questions This Section Answers

  • Who is Corebridge Financial best suited for among buyers with a heart disease history?
  • Is Corebridge Financial a good fit for a senior with heart disease who needs final-expense coverage?

Corebridge is best suited for four buyer profiles, based on platform agreement.

Applicants with stable, well-documented heart disease who want traditional term or permanent coverage and will complete medical underwriting [88]. Applicants with specific diagnoses where independent analysis has historically favored Corebridge — pericarditis, aortic stenosis, mitral stenosis, and post-bypass cases several months out from surgery [90]. Applicants who want flexible term durations, since Select-a-Term spans 10 to 35 years [92]. And applicants age 50–80 who cannot qualify for standard underwriting and need modest final-expense coverage through SimpliNow Legacy or Guaranteed Issue Whole Life [94].

Buyers who value conversion optionality also fit: Select-a-Term converts to permanent coverage without new medical evidence [97].

Probably Not Best Suited For

Questions This Section Answers

  • Who should not choose Corebridge Financial for life insurance with a heart disease history?
  • Is Corebridge Financial a poor fit for someone with a recent heart attack or unstable cardiac condition?

Several buyer profiles should look elsewhere or proceed cautiously.

Applicants with a recent, severe, or unstable cardiac event who need predictable eligibility before applying [99]. Buyers seeking guaranteed approval for substantial term or permanent coverage — no such product exists in this portfolio [99]. Applicants needing large death benefits at the lowest possible premium, since permanent options cap at $25,000–$35,000 [101]. Buyers who require immediate full benefits and cannot accept a first-two-year limitation on simplified or guaranteed-issue coverage [104].

Consumers who prioritize customer satisfaction scores should weigh the J.D. Power ranking of No. 19 of 22 and elevated regulatory complaint ratios [106]. Applicants with comorbid mental health conditions may also find Corebridge's underwriting historically weaker for that population [100]. And buyers under 50 cannot access the guaranteed-issue fallback, which is age-restricted [108].

When Another Option May Be Better

Questions This Section Answers

  • What is a better alternative to Corebridge Financial for a heart disease buyer who needs a large death benefit?
  • When should a heart disease applicant use an impaired-risk broker instead of applying directly to Corebridge Financial?

Platforms identified several situations where a different carrier or approach is preferable.

When the applicant needs a larger death benefit than Corebridge's permanent products allow, a carrier with stronger bespoke impaired-risk underwriting may be better than guaranteed-issue whole life [110]. When the applicant is under 50 and needs guaranteed-issue coverage, another carrier is required because Corebridge's GIWL is age-restricted [110]. When the cardiac history is complex, recent, or unstable, a broker specializing in impaired-risk life insurance may match the case better than a general direct product [112].

For applicants under 40 in excellent health seeking absolute lowest rates, Banner Life or Protective Life may offer slightly lower premiums [114]. For buyers who need a fully online, no-exam simplified-issue decision, comparing multiple simplified-issue carriers is advisable [115]. And when another carrier's underwriting guide is more favorable for the specific condition — stable coronary artery disease, prior bypass, valve disease, or remote myocardial infarction — that carrier may win the case [113].

The recurring platform recommendation is to use an independent broker who can obtain informal or preliminary underwriting opinions from multiple insurers before submitting a formal application [113].

Questions to Verify Before Buying

Questions This Section Answers

  • What should a buyer confirm with Corebridge Financial before signing a heart disease life insurance contract?
  • Which legal insurer issues Corebridge Financial policies, and is the product available in my state?

The platforms converged on a verification checklist. Confirm which legal insurer will issue the policy in your state and whether the exact product is currently available there [116]. Ask whether an informal or tentative underwriting opinion can be obtained before a formal application [116]. Confirm whether your application qualifies for Agile Underwriting+ and what information could still trigger an exam, labs, or physician records [117].

For simplified and guaranteed-issue products, verify minimum and maximum face amounts, age limits, state restrictions, and the exact death benefit during the first two years [119]. Confirm exclusions, graded benefits, suicide provisions, and contestability terms in the policy form [122]. Ask about the guaranteed premium schedule and lapse rules, including the reported 60-day window [124]. Finally, compare the offered premium and coverage against at least two other insurers that review applicants with heart disease [116].

Final AI Consensus Verdict

Corebridge Financial is a legitimate but mixed fit for life insurance with a heart disease history. Four of seven platforms named it during ranking discovery, with an average listed rank of 3.0 and a best rank of 1. Its strongest asset is portfolio breadth: fully underwritten Select-a-Term with flexible durations and no-exam conversion, simplified-issue SimpliNow Legacy, and no-health-question Guaranteed Issue Whole Life as a fallback [126].

The limitations are equally clear. No platform verified heart-disease-specific approval rates, table ratings, or premiums. Independent reviewers conflict on whether Corebridge's historical heart-disease underwriting edge persists, with one 2026 review calling it "hit or miss" since 2024 [129]. Customer satisfaction ranks near the bottom of J.D. Power's 2025 study [131]. Guaranteed-issue coverage caps at $25,000 with a two-year limited benefit [132].

The practical verdict: worth quoting, especially for stable cardiac histories or final-expense needs, but not worth relying on without a multi-carrier comparison and a preliminary underwriting opinion. AI-platform agreement here reflects repeated independent mentions, not proof of underwriting quality.

How This Review Was Produced

This fit review was generated from seven AI platform research responses collected for the topic "Best Life Insurance for People With Heart Disease," using the run research date of 2026-09-22. Each platform independently researched which carriers are worth considering for applicants with heart disease and returned fit assessments, product findings, pricing notes, and verification questions. Corebridge Financial was evaluated only against this use case. Ranking statistics reflect how many platforms named the entity during ranking discovery, not how many produced fit research. All citations are platform-reported evidence and were not independently verified by the writer stage.

Methodology Limitations

Several limitations apply. Platform-reported research dates differ from the authoritative run date: deepseek's response is dated 2026-01-15 while the run date is 2026-09-22, so its findings may be stale. Deepseek's research ran without search enabled, making its claims model-reported rather than retrieved. The deterministic identity audit flagged conflicting official domains and used an exact-name fallback; the matching domain remains unverified, and buyers should confirm the official site before transacting. Official-site retrieval failed for at least one mention, and no failed fetch was treated as a verified domain key.

Platform mentions count only platforms that named the entity during ranking discovery; three platforms produced fit research without naming it in that stage. Product naming conflicts — SimpliNow Legacy versus Simplified Issue Whole Life, and GIWL age ranges of 50–80 versus 50–85 — were not resolved by guessing. No heart-disease-specific pricing, approval rate, or table-rating schedule was publicly verified. The supplied URLs were collected from platform responses and were not independently validated. Citations are platform-reported evidence, not independently verified facts, and no-search model claims require verification before being treated as current.

From the index

Compare the adjacent findings before forming a view.

Sources

Company-Owned Sources

Independent Sources

Other Sources

  • Select-a-Term: https://adminplus.fgsfulfillment.com/View/corebridgefinancial/1/AGLC202276
  • Age and Amount Underwriting Requirements A: https://mylionstreet.com/media/Corebridge-A-A-reqs.pdf
  • Additional AI research evidence133 records
    1. AI research evidence record openai:c1
    2. AI research evidence record anthropic:27-5
    3. AI research evidence record anthropic:32-6
    4. AI research evidence record grok:web:2
    5. AI research evidence record anthropic:1-3
    6. AI research evidence record anthropic:1-5
    7. AI research evidence record grok:web:1
    8. AI research evidence record anthropic:30-1
    9. AI research evidence record anthropic:42-3
    10. AI research evidence record google:cit_locallife_heart
    11. AI research evidence record perplexity:c2
    12. AI research evidence record perplexity:c5
    13. AI research evidence record openai:c7
    14. AI research evidence record anthropic:2-6
    15. AI research evidence record anthropic:3-4
    16. AI research evidence record anthropic:4-1
    17. AI research evidence record anthropic:2-7
    18. AI research evidence record perplexity:c8
    19. AI research evidence record anthropic:33-12
    20. AI research evidence record deepseek:c3
    21. AI research evidence record anthropic:15-2
    22. AI research evidence record perplexity:c13
    23. AI research evidence record anthropic:27-6
    24. AI research evidence record anthropic:27-9
    25. AI research evidence record openai:c4
    26. AI research evidence record openai:c5
    27. AI research evidence record perplexity:c6
    28. AI research evidence record anthropic:27-1
    29. AI research evidence record anthropic:27-2
    30. AI research evidence record anthropic:21-2
    31. AI research evidence record perplexity:c7
    32. AI research evidence record deepseek:c1
    33. AI research evidence record google:cit_qol_details
    34. AI research evidence record google:cit_newhorizons_ltc
    35. AI research evidence record openai:c1
    36. AI research evidence record deepseek:c1
    37. AI research evidence record perplexity:c2
    38. AI research evidence record grok:web:16
    39. AI research evidence record anthropic:22-17
    40. AI research evidence record anthropic:22-18
    41. AI research evidence record anthropic:22-19
    42. AI research evidence record openai:c3
    43. AI research evidence record anthropic:21-2
    44. AI research evidence record perplexity:c7
    45. AI research evidence record anthropic:2-13
    46. AI research evidence record anthropic:4-1
    47. AI research evidence record deepseek:c4
    48. AI research evidence record anthropic:1-7
    49. AI research evidence record anthropic:1-8
    50. AI research evidence record anthropic:32-5
    51. AI research evidence record anthropic:32-6
    52. AI research evidence record grok:web:2
    53. AI research evidence record google:cit_nfg_rates
    54. AI research evidence record google:cit_insurancy_review
    55. AI research evidence record anthropic:13-3
    56. AI research evidence record anthropic:13-5
    57. AI research evidence record deepseek:c2
    58. AI research evidence record anthropic:27-5
    59. AI research evidence record anthropic:27-6
    60. AI research evidence record kimi:c1
    61. AI research evidence record kimi:c2
    62. AI research evidence record kimi:c5
    63. AI research evidence record google:cit_locallife_heart
    64. AI research evidence record openai:c4
    65. AI research evidence record google:cit_stent_recipients
    66. AI research evidence record kimi:c2
    67. AI research evidence record kimi:c5
    68. AI research evidence record openai:c8
    69. AI research evidence record anthropic:31-11
    70. AI research evidence record openai:c6
    71. AI research evidence record perplexity:c12
    72. AI research evidence record anthropic:15-2
    73. AI research evidence record perplexity:c13
    74. AI research evidence record perplexity:c5
    75. AI research evidence record perplexity:c7
    76. AI research evidence record perplexity:c2
    77. AI research evidence record anthropic:27-6
    78. AI research evidence record anthropic:40-1
    79. AI research evidence record anthropic:45-5
    80. AI research evidence record google:cit_nfg_rates
    81. AI research evidence record google:cit_insurancy_review
    82. AI research evidence record openai:c4
    83. AI research evidence record anthropic:22-17
    84. AI research evidence record anthropic:22-18
    85. AI research evidence record anthropic:22-19
    86. AI research evidence record openai:c3
    87. AI research evidence record anthropic:33-12
    88. AI research evidence record openai:c4
    89. AI research evidence record anthropic:1-1
    90. AI research evidence record anthropic:1-7
    91. AI research evidence record anthropic:1-8
    92. AI research evidence record openai:c7
    93. AI research evidence record anthropic:2-6
    94. AI research evidence record anthropic:27-1
    95. AI research evidence record anthropic:27-6
    96. AI research evidence record perplexity:c5
    97. AI research evidence record anthropic:15-2
    98. AI research evidence record perplexity:c13
    99. AI research evidence record openai:c4
    100. AI research evidence record anthropic:1-1
    101. AI research evidence record anthropic:13-1
    102. AI research evidence record anthropic:37-17
    103. AI research evidence record perplexity:c7
    104. AI research evidence record anthropic:22-17
    105. AI research evidence record openai:c3
    106. AI research evidence record anthropic:13-3
    107. AI research evidence record anthropic:13-5
    108. AI research evidence record perplexity:c2
    109. AI research evidence record perplexity:c5
    110. AI research evidence record perplexity:c2
    111. AI research evidence record perplexity:c5
    112. AI research evidence record perplexity:c12
    113. AI research evidence record openai:c4
    114. AI research evidence record anthropic:1-1
    115. AI research evidence record deepseek:c1
    116. AI research evidence record openai:c4
    117. AI research evidence record openai:c8
    118. AI research evidence record perplexity:c12
    119. AI research evidence record anthropic:27-1
    120. AI research evidence record anthropic:22-17
    121. AI research evidence record perplexity:c7
    122. AI research evidence record anthropic:22-19
    123. AI research evidence record openai:c3
    124. AI research evidence record anthropic:33-12
    125. AI research evidence record anthropic:1-1
    126. AI research evidence record openai:c1
    127. AI research evidence record anthropic:27-5
    128. AI research evidence record perplexity:c6
    129. AI research evidence record anthropic:32-6
    130. AI research evidence record grok:web:2
    131. AI research evidence record anthropic:13-5
    132. AI research evidence record anthropic:21-2
    133. AI research evidence record anthropic:22-17

Verify this research

Check when the research was run, which platforms were included, and what supports the findings.

Study date
September 22, 2026
Platforms analyzed
7
Source records
49
Ranking mentions
4 of 7
Platform share
57%
Final consensus rank
#7

Behind the findings

Platforms in this study

  • ChatGPT
  • Claude
  • DeepSeek
  • Grok
  • Perplexity
  • Kimi
  • Gemini

Source records

31 independent · 16 company-owned · 2 unclear

Evidence support

38 direct · 4 partial

Keep in mind

Use the run research_date as the study date. Platform-reported dates are provenance metadata and do not independently prove freshness.

Technical verification details

Use this SHA-256 fingerprint to identify the source snapshot associated with this study.

d3d100f65507248ad6e23185345ef6b3be2e3ba53da1f46621d8d39350a5a7de